The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial
- PMID: 28362208
- PMCID: PMC5489280
- DOI: 10.1080/21645515.2017.1288328
The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial
Abstract
A phase-1 clinical trial aimed to assess the safety and immunogenicity of the type-5 adenovirus vector based Ebola vaccine (Ad5-EBOV) was conducted in China. To provide more evidence for the safety evaluation and dose-selection, an exploratory sub-study using a wireless automatic temperature measuring platform was done based on the phase-1 clinical trial. The main aim of the sub-study was to obtain more information about the occurrence of fever and detect the potential associated factors, second was to assess the feasibility of the temperature measuring platform in vaccine clinical trials. Temperature data of 3 treatment groups all presented a rising tendency during the first 6 hours after vaccination, the incidence of elevated temperature and possible associated factors were analyzed. For the incidence of elevated temperature, no marked dose-response relationship was found in 6 hours with wireless thermometers; the information from mercury thermometers showed that the grade-1 fever proportion peaked at 6 hours and there was no difference between groups, while grade-2 fever proportion peaked at 24 hours and was significantly higher in high-dose group than those in the other 2 groups. Significant differences were found between sex groups (males vs. female, incidence rate ratios (IRR) = 2.93 and 7.62 for any-grade, grade-2 fever respectively, P<0.001); a decline in grade-2 fever incidence was found with the increasing age groups (IRR = 0.78, P = 0.003) and body mass index (BMI, IRR = 0.67, P<0.001) .Our findings show that the dose-dependent manner between fever and the dose of Ad5-EBOV in this study might emerge after 6 hours, and which is slight and transient. Wireless thermometers secured on the skin surface are not suitable for a long time (longer than 6 hours) measurement, new methods for temperature monitoring, like ear temperature measurement, should be tested in the further research.
Keywords: Ebola vaccine; Febrile reaction; Wireless automatic temperature measuring platform; phase-1clinical trial.
Similar articles
-
Open-label phase I clinical trial of Ad5-EBOV in Africans in China.Hum Vaccin Immunother. 2017 Sep 2;13(9):2078-2085. doi: 10.1080/21645515.2017.1342021. Epub 2017 Jul 14. Hum Vaccin Immunother. 2017. PMID: 28708962 Free PMC article. Clinical Trial.
-
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet. 2017 Feb 11;389(10069):621-628. doi: 10.1016/S0140-6736(16)32617-4. Epub 2016 Dec 23. Lancet. 2017. PMID: 28017399 Clinical Trial.
-
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.Lancet. 2015 Jun 6;385(9984):2272-9. doi: 10.1016/S0140-6736(15)60553-0. Epub 2015 Mar 25. Lancet. 2015. PMID: 25817373 Clinical Trial.
-
Ebola vaccines in clinical trial: The promising candidates.Hum Vaccin Immunother. 2017 Jan 2;13(1):153-168. doi: 10.1080/21645515.2016.1225637. Epub 2016 Oct 20. Hum Vaccin Immunother. 2017. PMID: 27764560 Free PMC article. Review.
-
Recent advances in the development of vaccines for Ebola virus disease.Virus Res. 2016 Jan 4;211:174-85. doi: 10.1016/j.virusres.2015.10.021. Epub 2015 Oct 24. Virus Res. 2016. PMID: 26596227 Review.
Cited by
-
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.Sci Rep. 2020 Apr 15;10(1):6478. doi: 10.1038/s41598-020-63634-z. Sci Rep. 2020. PMID: 32296104 Free PMC article.
-
Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens.Front Immunol. 2021 Jan 8;11:601170. doi: 10.3389/fimmu.2020.601170. eCollection 2020. Front Immunol. 2021. PMID: 33488596 Free PMC article. Review.
-
Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome.Pharm Res. 2024 Sep;41(9):1757-1773. doi: 10.1007/s11095-024-03761-8. Epub 2024 Aug 26. Pharm Res. 2024. PMID: 39187686 Review.
-
Recent advances and challenges of cellular immunotherapies in lung cancer treatment.Exp Hematol Oncol. 2025 Jul 7;14(1):94. doi: 10.1186/s40164-025-00679-8. Exp Hematol Oncol. 2025. PMID: 40624569 Free PMC article. Review.
References
-
- Centers for Disease Control and Prevention 2014 Ebola outbreak in West Africa-case counts. 2015. Available at: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html
-
- Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, Alimonti JB, Kobinger GP. mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013; 5:207ra143-207ra143; PMID:24132638; https://doi.org/10.1126/scitranslmed.3006605 - DOI - PubMed
-
- Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, et al.. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet 2015; 385:2272-9; https://doi.org/10.1016/S0140-6736(15)60553-0 - DOI - PubMed
-
- Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, et al.. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infectious Diseases 2015; 15:1156-66; PMID:26248510; https://doi.org/10.1016/S1473-3099(15)00154-1 - DOI - PMC - PubMed
-
- China Food and Drug Administration The standard guidelines for adverse reactions grading of vaccine clinical trials. http://www.sda.gov.cn/WS01/CL1036/9350_5.html. 2005.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical